|
Market Closed -
Hong Kong S.E.
04:08:20 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 29.30 HKD | -3.36% |
|
-7.04% | -16.09% |
| 08-27 | CanSino Biologics Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-26 | CanSino Biologics, deepGeneAI Agree to Develop Personalized mRNA Cancer Vaccines | MT |
Company Valuation: CanSino Biologics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 53,859 | 24,494 | 11,359 | 10,910 | 11,352 | 12,365 | - | - |
| Change | - | -54.52% | -53.62% | -3.96% | 4.05% | 8.93% | - | - |
| Enterprise Value (EV) 1 | 49,244 | 24,494 | 9,777 | 11,366 | 11,420 | 12,389 | 12,780 | 13,409 |
| Change | - | -50.26% | -60.08% | 16.25% | 0.47% | 8.48% | 3.16% | 4.92% |
| P/E | 19x | -16x | -3.64x | -19.3x | 285x | 57.3x | 19.2x | 7.96x |
| PBR | 4.54x | 1.97x | 1x | 1.49x | 1.56x | 1.22x | 1.13x | 0.99x |
| PEG | - | 0x | -0.1x | 0.3x | -3x | 0x | 0x | 0x |
| Capitalization / Revenue | 12.5x | 23.8x | 31.8x | 13.2x | 10.7x | 8.58x | 6.82x | 5.16x |
| EV / Revenue | 11.5x | 23.8x | 27.4x | 13.8x | 10.8x | 8.6x | 7.05x | 5.6x |
| EV / EBITDA | 24.4x | -20.5x | -5.58x | -65.4x | 51.2x | 62.3x | 48.8x | 39x |
| EV / EBIT | 25.4x | -17.9x | -5.17x | -28.2x | 258x | 111x | 135x | 75.3x |
| EV / FCF | 58.1x | -8.55x | -6.4x | -18.2x | -68.8x | 10.5x | 107x | 25.8x |
| FCF Yield | 1.72% | -11.7% | -15.6% | -5.5% | -1.45% | 9.5% | 0.93% | 3.88% |
| Dividend per Share 2 | 0.8 | - | - | - | - | - | - | - |
| Rate of return | 0.54% | - | - | - | - | - | - | - |
| EPS 2 | 7.74 | -3.68 | -5.87 | -1.53 | 0.11 | 0.4361 | 1.3 | 3.136 |
| Distribution rate | 10.3% | - | - | - | - | - | - | - |
| Net sales 1 | 4,300 | 1,031 | 357.1 | 824.9 | 1,059 | 1,440 | 1,812 | 2,396 |
| EBITDA 1 | 2,014 | -1,194 | -1,752 | -173.7 | 223 | 199 | 262 | 344 |
| EBIT 1 | 1,941 | -1,369 | -1,890 | -403.4 | 44.26 | 111.8 | 95 | 178 |
| Net income 1 | 1,914 | -909.4 | -1,447 | -378.5 | 27.87 | 40 | 322.2 | 778.7 |
| Net Debt 1 | -4,614 | - | -1,582 | 456.9 | 68.83 | 24.02 | 415.1 | 1,044 |
| Reference price 2 | 146.80 | 59.04 | 21.38 | 29.60 | 31.38 | 24.97 | 24.97 | 24.97 |
| Nbr of stocks (in thousands) | 247,450 | 246,766 | 247,044 | 247,044 | 247,044 | 247,044 | - | - |
| Announcement Date | 2/25/22 | 2/27/23 | 2/23/24 | 2/27/25 | 3/30/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 59.25x | 8.76x | 38.6x | -.--% | 1.88B | |
| 35.75x | 12.79x | 26.94x | 0.55% | 1,106B | |
| 37.14x | 6.26x | 17.62x | 2.1% | 612B | |
| 36.08x | 8.31x | 17.14x | 2.43% | 500B | |
| 20.6x | 4.98x | 12.38x | 2.63% | 367B | |
| 104.7x | 5.86x | 25.15x | 2.37% | 354B | |
| 21.05x | 5.51x | 13.55x | 2.9% | 286B | |
| 21.56x | 4.37x | 12.5x | 2.02% | 256B | |
| 26.98x | 6.96x | 12.46x | 2.37% | 230B | |
| -44.72x | 6.87x | 26.59x | 2.15% | 190B | |
| Average | 31.84x | 7.07x | 20.29x | 1.95% | 390.2B | |
| Weighted average by Cap. | 34.42x | 8.11x | 19.90x | 1.85% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6185 Stock
- Valuation CanSino Biologics Inc.
Select your edition
All financial news and data tailored to specific country editions
